Beam proves it can correct mutation; Pfizer to collaborate with Enodia

Phase 1positivePositive

AI Analysis

Summary

Beam Therapeutics shared initial Phase 1/2 data demonstrating its base editing therapy can correct mutations in glycogen storage disease type Ia. Pfizer announced a collaboration with Enodia.

Clinical Trial Data

Phase

1/2

Outcome Details

Beam proved it can correct mutation in rare disease gene editing therapy

Importance:7/10

Sentiment:

0.70

gene editingbase editingrare diseaseglycogen storage diseasecollaborationclinical trial

Related Companies

$BEAM $PFE

Read the original article

Published by Endpoints News on October 13, 2026 3:37 PM

Read Original